IM Cannabis Corp (NASDAQ:IMCC), a multinational cannabis company, has reported a revenue increase in its Third Quarter 2024 Earnings Call, with a notable contribution from its German operations. CEO Oren Shuster and CFO Uri Birenberg presented the earnings on November 14, 2024, highlighting the company's efforts to integrate operations in Israel and Germany to improve supply chain efficiency. Despite a challenging environment in Israel and a net loss increase, the company saw a 12.2% rise in revenue to $13.9 million compared to the same quarter last year. IM Cannabis also reported a significant improvement in efficiency and a narrowed EBITDA loss for the quarter.
Key Takeaways
- IM Cannabis reported a 12.2% increase in Q3 revenue to $13.9 million, with German revenue up 278%.
- Average selling price per gram rose to $6.2, a 42% increase.
- Operating expenses decreased, improving the operating expense ratio to 30%.
- Challenges in Israel include an ongoing war and a 10% decline in medical cannabis patients.
- Gross profit for the nine months ending September 30, 2024, decreased by 36% to $5.8 million.
- Net loss for the nine months increased to $10.6 million from $6.7 million in 2023.
- The company aims to finance operations through existing resources and credit facilities, with a focus on growth in Germany by 2025.
Company Outlook
- IM Cannabis is working on establishing a solid foundation for accelerated growth, particularly in Germany by 2025.
- The company plans to finance its operations through existing and future working capital and credit facilities, while also exploring additional capital sources.
Bearish Highlights
- The net loss for the nine months increased to $10.6 million, up from $6.7 million the previous year.
- Total (EPA:TTEF) assets decreased to $44.6 million, largely due to the cancellation of the Oranim agreement.
- Total liabilities increased to $40.4 million from $35.1 million.
Bullish Highlights
- Revenue growth was driven by increased sales in Germany, with a 278% increase in German revenue.
- The company saw a 25% improvement in efficiency due to reduced operational costs and increased revenue.
- The EBITDA loss for Q3 2024 narrowed significantly, marking an 82% improvement compared to Q3 2023.
Misses
- Gross profit for the nine months ended September 30, 2024, was down 36% from the previous year.
- The cost of revenue rose by 23%, primarily due to higher material costs.
- In Israel, the company faced challenges such as an ongoing war and a decline in medical cannabis patients.
Q&A Highlights
- CEO Oren Shuster emphasized the focus on building a strong foundation for growth in 2025, especially in Germany.
- The company discussed its strategies for integrating Israeli and German operations to enhance supply chain efficiency and reduce costs.
IM Cannabis, under the ticker IMCC, is navigating a complex market with strategic focus on efficiency and growth, particularly in the German sector. Despite the operational challenges in Israel and an overall net loss, the company's efforts to streamline operations and capitalize on favorable market conditions in Germany have led to revenue growth and improved efficiency. As IM Cannabis continues to adapt to market demands and explore financial strategies, it aims to solidify its presence and prepare for a stronger performance in the coming year.
InvestingPro Insights
IM Cannabis Corp (IMCC) has shown resilience in a challenging market, as evidenced by its recent financial performance. According to InvestingPro data, the company's revenue for the last twelve months as of Q2 2024 stood at $36.46 million, with a quarterly revenue growth of 11.68% in Q2 2024. This aligns with the reported 12.2% increase in Q3 revenue mentioned in the earnings call, indicating a consistent growth trajectory.
Despite the revenue growth, InvestingPro Tips highlight that IMCC is not profitable over the last twelve months, which is reflected in the negative operating income of $9.64 million for the same period. This corresponds with the increased net loss reported in the article, underscoring the company's ongoing financial challenges.
The stock's recent performance has been notably strong, with InvestingPro data showing a significant 43.59% return over the last week and a 20.69% return over the last month. This positive momentum could be attributed to the company's improved efficiency and narrowed EBITDA loss reported in the earnings call.
However, investors should note that according to InvestingPro Tips, IMCC's stock price movements are quite volatile, and the RSI suggests the stock is in overbought territory. This volatility aligns with the company's current state of transition and the challenging market conditions described in the article.
For those interested in a deeper analysis, InvestingPro offers 8 additional tips for IMCC, providing a more comprehensive view of the company's financial health and market position.
Full transcript - IM Cannabis Corp (IMCC) Q3 2024:
Operator: Good morning, and welcome to IM Cannabis' Third Quarter 2024 Earnings Conference Call. Today's conference call is being recorded. At this time, I would like to turn the conference call over to Anna Taranko, Director of Investor and Public Relations. Anna?
Anna Taranko: Good morning, and thank you, operator. Joining me for today's call are IM Cannabis' Chief Executive Officer, Oren Shuster, and Chief Financial Officer, Uri Birenberg. The earnings press release that accompanies this call is available on the Investor Relations section of our website at investors.imcannabis.com. Today's call will include estimates and other forward-looking information and statements, including statements concerning future results of operations, economic conditions and anticipated courses of actions, and are based on assumptions, expectations, estimates and projections as the date hereof. This information may involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences are described in detail in the Company's most recent filings available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. Furthermore, certain non-IFRS measures will be referred to during this call, and the term non-IFRS adjusted EBITDA loss will hereafter be referred to as adjusted EBITDA loss. Any estimates or forward-looking information or statements provided are accurate only as of the date of this call, and the Company undertakes no obligation to publicly update any forward-looking information or statements or supply new information regarding the circumstances after the date of this call. Please also note that all references on this call reflect currency in Canadian dollars unless otherwise stated. With that, it is my pleasure to turn the call over to Oren Shuster, CEO of IM Cannabis. Oren, please go ahead.
Oren Shuster: Thank you, Anna. Good morning, everyone, and thank you for joining us today. In the Q3, we had a clear focus to build a solid foundation to deliver accelerated growth in Germany in 2025. That said as the medical cannabis company active in Israel and in Germany, I will start with the quick overview of the development of the German market and our performance there before explaining the progress we made to position the company for 2025. Since the April 1 partial legalization, the German cannabis market has been experiencing unprecedented growth at the speed that I don't think many anticipated. The growth has been driven by the increasing number of patients opting for cannabis-based treatments and a relatively inexpensive, easy prescription process. Advances in medical research, better accessibility through pharmacies, and a growing number of health care professionals willing to prescribe cannabis for a range of conditions from chronic pain to anxiety and sleep disorders are also key factors. The easing of regulations and increased public awareness have contributed significantly to the expansion of the market as well. As I did in the last quarter, I would like to put this growth into perspective by taking you through the details of our sales in Germany in 2024. They clearly show that strategic shift we made to concentrate our resources on the German market was the right one. Our sales increased by over 200% in Q2 versus Q1 to reach $3.5 million. In Q3, we again increased our sales by 66% versus Q2 to reach $5.8 million in Q3. Since Q2, we have been driving the market growth and are positioned among the top cannabis companies in Germany. While I am very proud to presenting these numbers, our focus in the last few months has actually been behind the scenes on building a solid foundation for 2025. We spent the quarter leaning further into a clear target, full integration of the German and Israeli teams. The goal was to build a strong, consistent supply chain and a laser focus on how to improve the efficiency and accuracy of how we use our resources. I believe that this foundation will be the basis to drive accelerated growth in Germany in 2025. Behind every success, there is a strong unified team. In Q2, the Israeli and German colleagues started working very closely to build the new supply channel Israel to Germany. Cannabis supply chains are notoriously difficult to build with all the local, regional, and international regulations that need to be followed. They managed this in a record time. The first three Israeli grown strains launched in Q3. The teamwork behind these first three strains is gathering steam and has led to new projects and opportunities. We are in the process of on onboarding several new suppliers and expect to see the results during 2025. Just as important as a stable supply chain to deliver growth is sufficient resource management to sustain the growth. Our Q3 2024 revenues increased from $12.4 million in Q3 2023 to $13.9 million this quarter, while our operating expenses decreased from $4.9 million in Q3 2023 to $4.1 million in Q3 2024. As a result, our operating expenses ratio was 30% in Q3 2024 in comparison with 40% in Q3 2023, a remarkable 25% increase in efficiency. This decrease has been driven by several factors, but the integration between the two teams has been fundamental. By sharing the same resources, we have been able to significantly lower costs. Our active cost management has stretched through all aspects of the business, from purchasing and logistics to sales and marketing, making our execution much more efficient. Our goal is to keep this foundation to drive sustainable growth in 2025. While our journey to lean an agile company over the last year has not always been easy, I'm very proud of how efficient we have become, how well we are using our resources to deliver growth. The progress we have already made on both the supply chain and our sales efficiency gives us a very strong foundation to deliver accelerated growth in Germany in 2025. Taking a look at our Israeli business, as in Q2, we continue to shift resources to support the German business and continue to work toward maximizing our profitability in Israel. For our Israeli business, this translates into a clear focus on the premium and ultra-premium markets. Over the past few months, our market has been influenced by several factors. The ongoing war has continued to impact our supply chain, causing delays in shipments. We have also seen reduction in the number of medical cannabis patients with a decline of 10% from July to October. While the war initially delayed the medical cannabis license renewal process, it does not explain the sustained decrease. In the absence of sufficient data, we assume that the changes brought about by the July 2024 reform are causing complications in the prescription process. On the operational level, in our Israeli business, we relaunched LOT420, a premium Canadian brand with a total of 3 strains. All 3 strains were very well received by the market selling through quickly. The same occurred with Super Sativa, the leading strain in our INC craft brand. These results clearly show on how we can capitalize on our understanding of both the premium market drivers as well as the patient's needs to deliver sales. As in the previous quarters, we are continuing to clean our slow moving nonpremium stock, clearing out old inventory for about $0.6 million, which again impacted our cost of sales, gross margin, and gross profit. To sum up, Q3 2024, while the growth I'm seeing delivered in Germany is clearly a highlight, most importantly, we focused on building a solid foundation, fully integrating the two teams to strengthen our supply chain and drive efficiencies that will be basis to deliver accelerated growth in 2025 in Germany. I will now hand the call over to Uri, who will review the Q3 2024 financial results. Uri?
Uri Birenberg: Thank you, Oren. Our Q3 results were mainly impacted by the following points. Our revenue in Q3 increased by 12.2% versus Q3 2023. This growth was driven mainly by increase of 278% in the German revenue. Our selling price per gram of dried flower increased 42% in this time period to $6.2 per gram. In addition, our operating expenses decreased by 16% versus Q3 2023. We continued closely monitoring our inventory and accrued for about $0.6 million for slow moving stock. The mid-April or an in-agreement revocation resulted in reduced revenue and expenses versus previous periods. I will now take you through the overview of the Q3 2024 financial results for the company's operations. Revenue for the nine months ended September 30, 2024, and 2023 were $40.7 million and $38.1 million respectively, representing an increase of $2.6 million or 7%. The increase is mainly attributed to the accelerated growth in Germany with an increase in revenue of $6.3 million and decreased revenue in Israel of $3.7 million net. The decrease in Israel is attributed to the Oranim deal cancellation, which resulted in a decrease in revenue of approximately $5.1 million compared to the nine months ended September 2023. Excluding the Oranim revenue in q three 2023, we had an increase of revenue in Israel as well of approximately $1.4 million or 6%. Revenue for the three months ended September 30, 2024, 2023 were $13.9 million and $12.4 million respectively, representing an increase of $1.5 million or 12%. The increase is mainly attributed to the accelerated growth in Germany with an increase in revenue of $4.3 million and decreased revenue in Israel of $2.8 million net. The decrease in Israel is attributed to the Oranim deal cancellation, which resulted in decrease in revenue of $3.2 million compared to the three months ended September 2023. Excluding the Oranim revenue in Q3 2023, we have an increase in revenue as well in Israel of approximately $0.4 million or 5%. Total dried flower sold for the nine months ended September 30, 2024 was 6,408 kg at an average selling price of $6.01 per gram compared to 6,528 kg for the same period in 2023 at an average selling price of $5.34 per gram. For the three months ended September 30, 2024, total dried flower sold was 2,202 kg at an average selling price of $6.2 per gram compared to 2,558 kg for the same period in 2023 at an average selling price of $4.35 per gram, mainly attributed to the inventory life cycle, products diversity, discounts given, and increased competition in the region. For the nine and three months ended September 30, 2024, Germany's share of total revenue has significantly increased compared to the corresponding period in 2023. This increase has had a considerable impact reflecting in a higher average price due to the favorable market conditions and growing demands. Together, these factors have contributed to an overall positive effect on our revenue performances. The cost of revenue for the nine months ended September 30, 2024 and 2023 were $34.9 million and $28.4 million respectively, representing an increase of $6.5 million or 23%. This is mainly due to increase of material cost of approximately $7.1 million, of which clearing all raw material of approximately $0.94 million accrued for slow inventory of approximately $2.2 million and increased inventory sales resulted with an increase of approximately $4 million, which is offset by reducing other cost net of approximately $0.6 million. The cost of revenue for the three months ended September 30, 2024, and 2023 were $10.7 million and $9.6 million respectively, representing an increase of $1.1 million or 11%. This is mainly due to the increased cost of approximately $1.2 million, including an accrual of $0.6 million for slow inventory. This is offset by a decrease in other costs net of approximately $0.1 million. Gross profit for the nine months ended September 30, 2024, and 2023 were $5.8 million and $9 million respectively, representing a decrease of $3.2 million or 36%. Gross profit for the three months ended September 30, 2024, and 2023 were $3.1 million and $2.6 million respectively, representing an increase of $0.5 million or 19%. Gross profit including losses from realized fair value adjustment on inventory sold of $0.05 million and $0.7 million for the nine months ended September 30, 2024, and 2023, respectively. Gross margin after fair value adjustment in the nine months ended September 30, 2024 and 2023, respectively, were 14% versus 25%, and 23% versus 21% for the three months ended September 30, 2024 and 2023. G&A expenses for the nine months ended September 30, 2024, and 2023 were $6.8 million and $7.7 million respectively, representing a decrease of $0.9 million or 11%. General and administrative expenses for the three months ended September 30, 2024 and 2023 were $2.4 million and $2.1 million respectively, representing an increase of $0.3 million or 10%. The G&A expenses are comprised mainly from salaries to employees in the amount of $1.6 million and $0.5 million for the nine and three months ended September 30, 2024, Professional fees in the amount of $2.3 million and $0.9 million and for the nine and three months ended September 30, 2024. Depreciation and amortization in amount of $0.4 million and $0.14 million for the nine and three months ended September 30, 2024. Interest cost of amount of $1 million and $0.34 million for the nine and three months ended September 30, 2024, and other expenses in a total amount of $1.5 million for the nine and three months ended September 30, 2024. Selling and marketing expenses for the nine months ended September 30, 2024, and 2023 were $5.3 million and $8 million respectively, representing a decrease of $2.7 million or 34%. Selling and marketing expenses for the three months ended September 30, 2024 and 2023 were $1.5 million and $2.6 million respectively, representing a decrease of $1.1 million or 41%. The decrease in selling and marketing expenses for the nine and here months ended September 30, 24 is mainly attributed to our Oranim revoke agreement of approximately $1.3 million and $0.7 respectively. In addition to a decrease of $1.4 million and $0.3 million respectively in selling and marketing expenses. Total operating expenses for the nine months ended September 2024 and 2023 were $15.2 million and $16.6 million. In Q 2024, the total operating expenses were $4.1 million compared to $4.9 million in Q3 2023, a decrease of $0.8 million or 16%, mainly due to decrease in salaries of approximately $0.3 million, depreciation expenses of $0.2 million, and insurance of $0.1 million. Operating expenses ratio for the nine months ended September 30, 2024 was 31%, excluding the one-time expense outcome of Oranim deal cancellation, versus 44% for the nine months ended September 30, 2023, representing an increased efficiency of about 30%. Operating expenses ratio for the three months ended September 30, 2024 was 30% versus 40% for the three months ended September 30, 2023, representing an increased efficiency of about 25%. The efficiency ratio improvement is resulting from decreased operational cost and increased revenue. Non-IFRS adjustment EBITDA loss for the nine months ended September 2024 and 2023 was $4.7 million compared with $3.7 million representing an increase of 25%. Non-IFRS adjustment EBITDA loss in Q3 2024 was $0.2 million compared to an EBITDA loss of $1.3 million in Q3 2023, representing an increase of 82%. Net loss in the nine months ended September 2024 was $10.6 million compared to $6.7 million in the nine months ended September 2023. Net loss in Q3 2024 was $1.1 million compared to $2.1 million in Q3 2023. Diluted loss per share for the nine months ended September 2024 was $4.29 compared to a loss of $2.95 per share in the same period for year 2023. Diluted loss per share for Q3 2024 was $0.41 compared to a loss of $0.96 per share in Q3 2023. As of the balance sheet, cash and cash equivalents as of September 30, 2024 were $2 million compared to $1.8 million on December 31, 2023. Total assets as of September 30, 2024 were $44.6 million compared to $48.8 million on December 31, 2023, a decrease of $4.2 million or 8.6%. The decrease is mainly attributed to the Oranim agreement cancellation of $9.5 million, of which mainly attributed to goodwill of $3.5 million, intangible asset $1.4 million, inventory $0.8 million, trade receivables $1.3 million, property, plant and equipment $0.8 million, and reduction of cash and cash equivalent of approximately $0.3 million. In addition to Oranim revocation agreement effect, there is a total asset increase of $5.3 million, mainly due to increase of $8.1 million in trade receivables and increase of cash and cash equivalent of $0.5 million, offset by $4.8 million reduction in inventory and reduction of $0.9 million in intangible assets. Total liabilities as of September 30, 2024 were $40.4 million compared to $35.1 million on December 31, 2023, an increase of $5.3 million or 15%. The decrease was mainly due to the Oranim agreement cancellation of $6.8 million, of which mainly attributed to put option liability $2 million, purchase consideration payable $2.2 million, trade payables $1.6 million, lease liabilities $0.4 million, and a decrease of $0.3 million in deferred tax liability. In addition to the Oranim revocation agreement effect, there is a total liability increase of $12.1 million, mainly due to increase of $8.9 million in trade payables and an increase of $1.6 million in other accounts payable. The company is planning to finance its operation from existing and future working capital resources as well as from available credit facilities, and we'll continue to evaluate additional sources of capital and financing as needed. I would now like to turn the call back to you Oren for closing remarks. Oren?
Oren Shuster: Thank you, Uri. While the growth we delivered in Germany this quarter is a highlight, we spent the quarter focused on building a solid foundation for 2025. We leaned further into the full integration of the German and Israeli teams. Our goal was to build a strong, consistent supply chain, along with a laser focus on how to improve the efficiency and accuracy of how we use our resources. I believe that the foundation we built this quarter will be the basis to drive further accelerated growth in Germany in 2025. I will now end the call over to the operator to begin our question-and-answer session. Operator? Speaker 0:
Operator:
Anna Taranko: There are no questions. So thank you operator and thank you all for joining our call today.
Operator: [Operator Closing Remarks].
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.